Medtronic Expand URO U.S. clinical trial meets safety and effectiveness primary endpoints for Hugo™ robotic-assisted surgery system

Rhea-AI Summary

Medtronic (NYSE: MDT) announced successful results from its Expand URO clinical trial for the Hugo™ robotic-assisted surgery (RAS) system. The study, the largest multi-center prospective Investigational Device Exemption (IDE) trial for multi-port robotic-assisted urologic surgery in the U.S., met both primary safety and effectiveness endpoints.

The trial included 137 patients undergoing urologic procedures. The American Urologic Association (AUA) described it as a 'practice-changing, paradigm-shifting (P2) clinical trial in urology'. Results were presented at the AUA annual meeting in Las Vegas by Dr. Michael R. Abern from Duke University Hospital, the study's national principal investigator.

Positive

• Successfully met both primary safety and effectiveness endpoints in largest U.S. robotic-assisted urologic surgery trial
• Submitted Hugo RAS system to FDA for regulatory review
• Received recognition as 'practice-changing, paradigm-shifting' trial by American Urologic Association

Negative

• None.

News Market Reaction – MDT

-0.14%

1 alert

-0.14% News Effect

On the day this news was published, MDT declined 0.14%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Largest multi-center prospective Investigational Device Exemption (IDE) study for multi-port robotic-assisted urologic surgery in the U.S. presented as a late-breaker at the American Urologic Association annual meeting
 
Company confirms Hugo RAS system submission to the U.S. Food and Drug Administration

GALWAY, Ireland and LAS VEGAS, April 26, 2025 /PRNewswire/ -- Medtronic (NYSE: MDT), a global leader in healthcare technology, today announced that the Expand URO Investigational Device Exemption (IDE) clinical study, the largest such study for robotic-assisted urologic surgery ever conducted, met both primary safety and effectiveness endpoints. The prospective, multi-center, single-arm IDE study included 137 patients who underwent urologic procedures using the Hugo™ robotic-assisted surgery (RAS) system.

The data, described by the American Urologic Association (AUA) as a "practice-changing, paradigm-shifting (P2) clinical trial in urology", was presented today at the AUA annual meeting in Las Vegas by Michael R. Abern, M.D., the study's national principal investigator and a urologic surgeon at Duke University Hospital in Durham, N.C.

"The study demonstrated that the Hugo RAS system met the safety and effectiveness endpoints, and the outcomes are consistent with published literature for robotic-assisted urologic surgery," said Dr. Abern. "Having performed the first case in the Expand URO clinical study, it's incredibly rewarding to see the results of this rigorous and important study in the field of robotic surgery."

About the Expand URO clinical study:

• On average, patients were approximately 63 years old and classified as American Society of Anesthesiologists (ASA) category ≥3, indicating they had severe systematic disease or condition impacting their overall health.
• 11 surgeons across 6 hospitals in the U.S. performed 3 types of urologic procedures — prostatectomies (prostate removal; n=55), nephrectomies (kidney removal; n=53), and cystectomies (bladder removal; n=29).
• The common patient cohorts were prostate cancer in prostatectomy, renal tumors in nephrectomy, and bladder tumors in cystectomy.
• The study was conducted with a high degree of rigor consistent with the FDA premarket requirements and included prospective enrollment and data collection, independent event adjudication by a Clinical Events Committee (surgeon advisory group), data monitoring and excellent follow-up compliance with approximately 98% of patients completing the 30-day follow-up.
• All cancer patients in the study will be followed for five years.^†

Expand URO study primary endpoint data:

• Safety: The rates of grade 3 or higher complications (3.7% prostatectomy, 1.9% nephrectomy, and 17.9% cystectomy) were favorably below the performance goals (20% prostatectomy, 20% nephrectomy, and 45% cystectomy; p=0.0006, p=0.0001, p=0.0025, respectively), which were established based on systematic review of published literature across all three cohorts.
• Effectiveness: The study's 98.5% surgical success rate was well above the performance goal of 85% (p<0.0001), which was established based on a systematic review of published literature. There were two conversions: one was related to the device and one was related to patient anatomy.

"The Expand URO clinical study provides important clinical evidence about the Hugo RAS system and is an exciting milestone that brings us closer to our goal of offering surgeons in the U.S. long-awaited choice in robotic technology," said James Porter, M.D., chief medical officer, Robotic Surgical Technologies and Digital Technologies within the Surgical business, part of the Medical Surgical portfolio at Medtronic, and a urologic surgeon at Swedish Medical Center in Seattle, WA. "Surgeons want to deliver the best care to our patients and robotic technology is key to making that possible today by enabling minimally invasive surgery and leveraging technology that is shaping the future of surgery."

U.S. FDA submission for the Hugo RAS system
Medtronic also announced today that it submitted the Hugo RAS system to the U.S. Food and Drug Administration (FDA) for a urologic indication in the first quarter of calendar 2025.

The FDA submission is the company's latest milestone toward a planned entrance into the U.S., the world's largest robotic surgery market. In February, the company shared that it completed enrollment in both its hernia and benign gynecology (GYN) studies and received approval to start a new clinical study including oncologic GYN procedures — all in support of planned submissions to the FDA for additional indications beyond urology for the Hugo RAS system in the U.S.

Outside the U.S., the Hugo RAS system is in clinical use in more than 25 countries across 5 continents, with a growing body of evidence including more than 200 independent papers published to date.

Medtronic thoughtfully designed the Hugo RAS system — through collaboration with hundreds of surgeons and hospital leaders globally — with the goal of expanding access to minimally invasive care to more patients around the world. The Hugo RAS system delivers the benefits of RAS in a flexible, modular form factor and open surgeon console that supports communication among the surgical team. Paired with the Touch Surgery™ ecosystem, the Hugo RAS system offers a smart, connected surgical experience that is shaping the future of surgery.^‡                                                                                                     

The Hugo RAS system is not cleared or approved in all markets. Regulatory requirements of individual countries and regions will determine approval, clearance, or market availability. In the U.S., the Hugo RAS system is an investigational device not for sale.

For more information, visit medtronic.com/hugo.

†The evaluation did not include assessment of outcomes related to the treatment of cancer or any specific treatment of any underlying disease or condition.

‡Touch Surgery ecosystem is not intended to direct surgery, or aid in diagnosis or treatment of a disease or condition; Live Stream and performance insights are only intended for education and training purposes.

About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic (NYSE: MDT), visit www.Medtronic.com and follow Medtronic on LinkedIn.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

Contacts:
Gary Jeanfaivre
Public Relations
+1-203-556-0777

Ryan Weispfenning
Investor Relations
+1-763-505-4626

View original content to download multimedia:https://www.prnewswire.com/news-releases/medtronic-expand-uro-us-clinical-trial-meets-safety-and-effectiveness-primary-endpoints-for-hugo-robotic-assisted-surgery-system-302438977.html

SOURCE Medtronic plc

FAQ

What were the results of Medtronic's Expand URO clinical trial for the Hugo robotic surgery system?

The trial met both primary safety and effectiveness endpoints, with outcomes consistent with published literature for robotic-assisted urologic surgery.

How many patients were involved in MDT's Expand URO clinical trial?

The clinical trial included 137 patients who underwent urologic procedures using the Hugo robotic-assisted surgery system.

What is the significance of the Expand URO trial for Medtronic (MDT)?

It is the largest multi-center prospective IDE study for multi-port robotic-assisted urologic surgery in the U.S., described as 'practice-changing' by the American Urologic Association.

Has Medtronic submitted the Hugo RAS system to the FDA?

Yes, Medtronic has confirmed submission of the Hugo robotic-assisted surgery system to the U.S. Food and Drug Administration.